Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
22.02
-2.14 (-8.86%)
At close: Mar 20, 2026, 4:00 PM EDT
22.21
+0.19 (0.86%)
After-hours: Mar 20, 2026, 5:44 PM EDT
Hims & Hers Health Stock Forecast
Stock Price Forecast
The 12 analysts that cover Hims & Hers Health stock have a consensus rating of "Hold" and an average price target of $28.83, which forecasts a 30.93% increase in the stock price over the next year. The lowest target is $17 and the highest is $68.
Price Target: $28.83 (+30.93%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Hims & Hers Health stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 2 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 8 | 8 | 7 | 8 | 9 | 11 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 12 | 12 | 12 | 13 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Hold Maintains $18 → $25 | Hold | Maintains | $18 → $25 | +13.53% | Mar 16, 2026 |
| Barclays | Barclays | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +31.70% | Mar 11, 2026 |
| Citigroup | Citigroup | Strong Sell → Hold Upgrades $13 → $24 | Strong Sell → Hold | Upgrades | $13 → $24 | +8.99% | Mar 10, 2026 |
| Deutsche Bank | Deutsche Bank | Hold Maintains $25 → $28 | Hold | Maintains | $25 → $28 | +27.16% | Mar 10, 2026 |
| B of A Securities | B of A Securities | Sell → Hold Upgrades $13 → $23 | Sell → Hold | Upgrades | $13 → $23 | +4.45% | Mar 10, 2026 |
Financial Forecast
Revenue This Year
2.80B
from 2.35B
Increased by 19.27%
Revenue Next Year
3.30B
from 2.80B
Increased by 17.96%
EPS This Year
0.55
from 0.51
Increased by 6.60%
EPS Next Year
0.71
from 0.55
Increased by 29.73%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.0B | 3.7B | |||
| Avg | 2.8B | 3.3B | |||
| Low | 2.4B | 2.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 26.6% | 33.3% | |||
| Avg | 19.3% | 18.0% | |||
| Low | 3.0% | -4.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 1.28 | 1.03 | ||
| Avg | 0.55 | 0.71 | ||
| Low | -0.05 | 0.21 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 150.1% | 88.4% | ||
| Avg | 6.6% | 29.7% | ||
| Low | - | -62.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.